Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Committee Votes topic
No spam. Unsubscribe anytime.
House Energy executive actions: HJ16 tabled, SB163 amended and passed, HB538 advanced to floor
Summary
The House Energy Committee took multiple executive actions: it tabled House Joint Resolution 16, amended and concurred in Senate Bill 163 (neural‑privacy/privacy act), and advanced House Bill 538 (9‑1‑1 cleanup) to the House floor.
Get email alerts on the Committee Votes topic
No spam. Unsubscribe anytime.
During executive action the committee took three formal steps:
House Joint Resolution 16 — Motion to table: Representative Brewster moved to substitute and table HJ 16; the roll call recorded 8 ayes and 6 noes and the motion carried. Outcome: HJ 16 is tabled.
Senate Bill 163 — Amendment and concurrence: Senator Zollicoff’s SB 163, described by committee staff as a "privacy act" adding protections for neural data and related definitions, was amended (amendment SB163.001.004 clarifying the definition and de‑identified genetic data language) and the committee voted to concur with the bill as amended. The voice vote and proxy record show 14 ayes and no noes; proxies for Representative Fielder and Representative Mitchell were recorded as yes. Outcome: SB 163 concurred in by committee.
House Bill 538 — Executive action: Committee members voted to advance HB 538 to the House floor. A voice vote was recorded as 14 ayes and no noes; proxies were noted. Outcome: HB 538 moved to the floor.
Vote tallies as recorded in the hearing transcript: - HJ 16: 8 ayes, 6 noes (tabled) - SB 163 (amended): 14 ayes, 0 noes (concurred) - HB 538: 14 ayes, 0 noes (advanced to House floor)
Notes: SB163 amendment text clarified the bill’s definitions (neurotechnology and de‑identified genetic data) and was supported by committee discussion; SB 163 testimony emphasized brain‑privacy protections. HB 538 was advanced after proponents and program staff confirmed it does not change the dollar‑per‑line fee or the 75/25 distribution to PSAPs.
